

# agenda: all attendees



THURSDAY, NOVEMBER 9 - SATURDAY, NOVEMBER 11

A SESSIONS	B SESSIONS	C SESSIONS	D SESSIONS
Designed for healthcare professionals. CME/CE is provided unless noted otherwise. (*)	Designed for recently diagnosed patients and their caregivers.	Designed for those who have been living with PF for a while.	Designed for individuals who are not currently living with PF, such as transplant recipients and individuals who have lost a loved one.

While some sessions are tailored for attendees with specific experiences, you may attend **any** session that interests you.

**REGISTRATION**  
7:30 A.M. - 8:00 P.M.

**COMMUNITY PULMONOLOGISTS AND ILD FELLOWS (CME)**  
10:00 A.M. - 4:00 P.M. Pre-registration required

Protocol for evaluation of the patient with interstitial lung disease	Lisa Lancaster, MD
How to assess for autoimmune disease in your ILD patient	Aryeh Fisher, MD
Evaluating an occupational exposure history	Mridu Gulati, MD
MDD and an accurate diagnosis in ILD	David Lederer, MD
How to effectively read an HRCT and utilize its clues for differential diagnosis in ILD	Mary Salvatore, MD
Approach to pathological analysis of ILDs	Joyce Johnson, MD
<b>Lunch provided</b>	
Utility and options for lung biopsy: Emerging utility of bronchoscopic cryobiopsy	Fabien Maldonado, MD
Approved therapies for IPF: A review of the data	Sonye Danoff, MD
Safety and management of side effects of pirfenidone and nintedanib	Wendi Mason, MSN
Stem-cell and cell-based therapies in lung disease (paucity of data in just IPF)	Marilyn Glassberg, MD
Non-pharmacological management of IPF/ILD	Amy Olson, MD
Palliative care and hospice	Kathleen O. Lindell, PhD, RN

# agenda: all attendees



THURSDAY, NOVEMBER 9

Evaluation for lung transplant

Tim Whelan, MD

## PATIENTS AND CAREGIVERS: LUNCH

### TAKING AN ACTIVE ROLE IN YOUR IDIOPATHIC PULMONARY FIBROSIS (IPF) MANAGEMENT - PRESENTED BY GENENTECH



11:30 A.M. – 12:45 P.M.

Pre-registration is required and opens at the *Summit* at 11 A.M on Thursday.  
Open to tracks B, C, and D only.

## PATIENTS AND CAREGIVERS: INTRO TO THE PFF, NEED MEETS ACTION, AND UNDERSTANDING THE BASICS OF RESEARCH



1:00 P.M. – 4:00 P.M.

Introduction of the PFF and the Care Center Network

Kevin Flaherty, MD, MS

Research 101: Understanding the process, terminology, and definitions and how a drug is brought to market

Hal Collard, MD,  
PFF Ambassador,  
David McNinch

Q&A

All

Break (15 minute)

All

Need Meets Action Part I: Overview of volunteering at the PFF

PFF Development Team and  
Panel Volunteers

Need Meets Action Part II: Overview of effective fundraising

PFF Development Team and  
Panel Volunteers

Q&A

All

## FOCUS GROUPS

1:00 P.M. - 2:00 P.M

Focus Group 1 (1:00 P.M. - 2:00 P.M.)

Pre-registration required

Focus Group 2 (1:00 P.M. - 2:00 P.M.)

Pre-registration required

## FOCUS GROUPS

2:00 P.M. - 3:00 P.M

Focus Group 3 (2:00 P.M. - 3:00 P.M.)

Pre-registration required

Focus Group 4 (2:00 P.M. - 3:00 P.M.)

Pre-registration required

# agenda: all attendees



FRIDAY, NOVEMBER 10

**WELCOME RECEPTION AND POSTER PRESENTATION:  
SPONSORED BY VANDERBILT UNIVERSITY MEDICAL CENTER**  
5:00 P.M. - 8:00 P.M.



FRIDAY, NOVEMBER 10

**REGISTRATION** 7:00 A.M. - 8:00 P.M.

**BREAKFAST** 7:00 A.M. - 8:00 A.M.

**PLENARY SESSION I: PROMISE OF GENETICS AND PERSONALIZED  
MEDICINE IN PF (CME)**

8:00 A.M. – 10:00 A.M.



National Heart, Lung and Blood Institute (NHLBI) support for personalized therapy in lung disease

Jim Kiley, PhD

State-of-the-art approaches to genetic discovery in complex disease

Jeff Trent, PhD

Current status of clinical genetic testing in ILD

Jim Loyd, MD

A genetic counselor's perspective: Impact of genetic information for patients and families

Janet Talbert, MS, CGC

Panel discussion

Jim Kiley, Jeff Trent, Jim Loyd, Janet Talbert, Carolyn Adams-Duda, Heather Kagel

30 minute break and networking

All

**SESSION 1A: GENETICS OF ILD (CME)**

10:30 A.M. - 12:15 P.M.



Poster winner: Abstract talk I

TBA

Spectrum of telomere-related ILD

Mary Armanios, MD

Progression and outcome of telomere-related ILD

Christine Garcia, MD

New genes associated with familial ILD

Jon Kropski, MD

\* Results of whole genome sequencing in sporadic IPF

Brian Yaspan, PhD

**SESSION 1B, C, D: KIDBILLY MUSIC - PRESENTED BY GENENTECH**

10:30 A.M. – 12:15 P.M.



Perspectives from All: Songwriting for team-building, networking, and emotional healing

KidBilly Music

\* CME credit not provided

# agenda: all attendees



FRIDAY, NOVEMBER 10

## SESSION 2A: ENVIRONMENTAL INFLUENCES (CME)

A

1:15 P.M. - 2:50 P.M.

Poster winner: Abstract talk II

TBA

The microbiome in IPF

Phil Molyneaux, PhD

Gastroesophageal Reflux Disease (GERD) in ILD

Ganesh Raghu, MD

Sleep apnea in ILD

Lisa Lancaster, MD

Autoimmune mechanisms of pulmonary fibrosis: CTD-ILD

Aryeh Fischer, MD

## SESSION 2B: UNDERSTANDING ILD AND IPF

B

1:15 P.M. - 2:55 P.M.

Part I: Overview of ILD, IPF, and connective tissue disease

Kristin Highland, MD

Part II: Understanding your test results: HRCT, 6MWT, PFTs, and oximetry

Mary Beth Scholand, MD

Q&A

All

## SESSION 2C: QUALITY OF LIFE: NEXT STEPS

C

1:15 P.M. - 2:55 P.M.

Part I: Evaluation for lung transplantation

Josh Mooney, MD, MS

Part II: Using mindfulness for stress management in chronic disease

Linda Manning, MD

Part III: Accupuncture, nutrition, and alternative therapies in chronic disease

Q&A

## SESSION 2D: CALL TO ACTION, PART I

D

1:15 P.M. - 2:50 P.M.

Part I: Transitioning after the loss of a loved one, after a transplant (two roundtables)

Kathleen O. Lindell, PhD,  
RN, John Mulder

Part II: How to participate in legislative advocacy

Bill Schmidt, Kate Gates

Group Activity

All

30 minute break and networking

All

## SESSION 3A: DISEASE MECHANISMS I (CME)

A

3:15 P.M. - 4:50 P.M.

Poster winner: Abstract talk III

# agenda: all attendees



FRIDAY, NOVEMBER 10

Pre-clinical modeling of telomerase deficiency

Role of aging and senescence in IPF

Epithelium as the guardian of the lungs: Response to injury

Mechanism of alveolar epithelial cell renewal: Impact on ILD

Paul Wolters, MD

Victor Thannickal, MD

Tushar Desai, MD, MPH

Paul Noble, MD

## SESSION 3B: OXYGEN THERAPY, PULMONARY REHABILITATION, AND SYMPTOM MANAGEMENT



3:15 P.M. – 4:55 P.M.

Part I: Living with oxygen therapy and PF

- » Overview of various types of POCs, compressed gas units, trans-fill systems, and backpacks
- » How can I be active and travel with O2 (MedJet and other emergency travel services)?

Susan Jacobs, RN, M

Part II: Pulmonary rehab: What is it and how can it help me?

Trina Limberg, BS, RRT

Part III: Symptom management: Cough, dyspnea and fatigue

Mary Streck, MD

Q&A

All

## SESSION 3C: WHAT'S IN THE PIPELINE? CURRENT CLINICAL TRIALS, POTENTIAL THERAPIES, AND HOW THE PROCESS WORKS



3:15 P.M. - 4:55 P.M.

Part I: Understanding how clinical trials work and the therapeutic process to bring a drug to market

Bill Bradford, MD, PhD

Part II: Current clinical drug trials in the pipeline for IPF and PF, and an overview of potential therapies moving forward

Gregory Cosgrove, MD

Q&A

All

## SESSION 3D: CALL TO ACTION PART II: HOW TO HOST A FUNDRAISING EVENT



3:15 P.M. - 4:55 P.M.

How to host a fundraising event

PFF Development Team

## NETWORKING COCKTAIL HOUR

5:30 P.M. - 6:30 P.M.



## SATURDAY, NOVEMBER 11

### NETWORKING DINNER WITH ENTERTAINMENT BY KIDBILLY MUSIC AND THE PFF COMMUNITY, PRESENTED BY GENENTECH

6:30 P.M. - 9:00 P.M.



## SATURDAY, NOVEMBER 11

**REGISTRATION** 7:00 A.M. - 4:00 P.M.

**BREAKFAST** 7:00 A.M. - 8:00 A.M.

### PLENARY SESSION II: MAXIMIZING THE IMPACT OF AVAILABLE THERAPIES IN IPF (CME)

8:00 A.M. – 10:00 A.M.



**KEYNOTE:** Re-thinking clinical trials in PF

PFF Care Center Network and PFF Patient Registry

Improving care for PF patients and adherence to treatment plans: A physician family member's perspective

**PANEL DISCUSSION:** Opportunities and obstacles to provide optimal care for PF in 2017

30 minute break and networking

Gordon R. Bernard, MD  
 Kevin Flaherty, MD, MS  
 Jason Martin, MD  
 Gordon R. Bernard, Kevin Flaherty, Jason Martin, Greg Cosgrove, Maryluz Fuentes, MD, Jane Nelson  
 All

### SESSION 4A: DIAGNOSIS OF IPF (CME)

10:30 A.M. - 12:15 P.M.



Poster winner: Abstract talk IV

Advances in HRCT imaging, quantitative HRCT imaging in IPF trials and clinical care

New approaches to diagnosis: Potential role for cryobiopsy

Pre-clinical ILD

Lessons from at-risk cohorts

TBA  
 Jonathan Goldin, MD, PhD  
 Fabien Maldonado, MD  
 Gary M. Hunninghake, MD  
 Tim Blackwell, MD

### SESSION 4B, C, D: BASICS OF GENETICS AND WHAT WE KNOW ABOUT STEM CELL THERAPY

10:30 A.M. - 12:15 P.M.



Part I: Genetics 101 in IPF

Jim Loyd, MD

\* CME credit not provided

# agenda: all attendees



**SATURDAY, NOVEMBER 11**

---

Part II: Stem cell therapies and biotourism

- » What is stem cell therapy and what is it approved for?
- » Stem cell centers in the community

Sonye Danoff, MD

Part III: Clinical trials with stem cells for ILD

Q&A

Marilyn Glassberg, MD

All

## **LUNCH AND NETWORKING (B, C GROUPS)**

12:15 P.M. - 1:15 P.M.



Lunch with people who live in your region

## **LUNCH AND NETWORKING (D GROUP)**

12:15 P.M. - 2:00 P.M.



Lunch off-site

PFF Staff

## **SESSION 5A: THERAPEUTICS (CME)**

1:15 P.M. - 2:50 P.M.



Poster winner: Abstract talk V

TBA

Drug development in IPF: What is on the horizon

Andy Limper, MD

\* Stem cell therapies: Real possibility or not?

Ramona Doyle, MD

Personalized medicine in IPF, integrating genetics in clinical trials

Imre Noth, MD

Role of biomarkers in diagnosis and treatment

Naftali Kaminski, MD

## **SESSION 5B, C: APPROVED THERAPIES FOR IPF AND DIAGNOSIS AND TREATMENT OF COMORBIDITIES IN ILD**

1:15 P.M. - 2:50 P.M.



Part I: Overview of pirfenidone and nintedanib

Joyce Lee, MD

Part II: Adherence to treatment plans: Safety and management of side effects with pirfenidone and nintedanib

Wendi Mason, MSN

Part III: How to qualify for reduced payment plans

Anne Turner, RN, BSN

### **Breakout Discussions: Diagnosis and Treatment of Comorbidities**

Obstructive sleep apnea (OSA)

Lisa Lancaster, MD

Gastroesophageal Reflux Disease (GERD)

Wendi Mason, MSN

Scleroderma

Kristin Highland, MD

\* CME credit not provided

# agenda: all attendees



**SATURDAY, NOVEMBER 11**

---

Sarcoidosis

Bob Baughman, MD

## SESSION 5D: CALL TO ACTION PART III: WHAT'S NEXT



2:30 P.M. - 4:00 P.M.

Planning for the future

PFF Staff

## FOCUS GROUPS

2:30 P.M. - 3:30 P.M.

Focus group 5 (2:30 P.M. - 3:30 P.M.)

Pre-registration required

Focus group 6 (2:30 P.M. - 3:30 P.M.)

## BREAK AND NETWORKING (GROUPS A, B, C)



2:50 P.M. - 3:15 P.M.

## SESSION 6A: DISEASE MECHANISMS II (CME)



3:15 P.M. - 4:50 P.M.

Poster Winner: Abstract Talk VI

TBA

Lessons from other rare genetic diseases - Hermansky-Pudlak Syndrome

Lisa Young

Mechanoregulation of matrix deposition and fibrosis progression

Dan Tschumperlin, PhD

Epithelial-fibroblast interactions in lung fibrosis

Kevin Kim, MD

Immune/inflammatory cells in IPF

Erica Herzog, MD, PhD

## SESSION 6B, C: ROUNDTABLE DISCUSSIONS



3:15 P.M. - 4:50 P.M.

Caregiver burnout

John Mulder

How to prepare for an effective clinical visit with your doctor

David Lederer, MD,  
Michele Peters

Depression and anxiety in chronic disease

Jim Jackson, PhD

Palliative and hospice care

Kathleen O. Lindell, PhD, RN

How to participate in legislative advocacy

Bill Schmidt, Kate Gates